NASDAQ:XERS

Xeris Pharmaceuticals Competitors

$4.23
-0.03 (-0.70 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.16
Now: $4.23
$4.29
50-Day Range
$4.16
MA: $4.82
$5.98
52-Week Range
$1.56
Now: $4.23
$7.94
Volume817,476 shs
Average Volume2.66 million shs
Market Capitalization$252.81 million
P/E RatioN/A
Dividend YieldN/A
Beta2.22

Competitors

Xeris Pharmaceuticals (NASDAQ:XERS) Vs. PAHC, ENTA, ARCT, AKRO, EPIX, and ANNX

Should you be buying XERS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Xeris Pharmaceuticals, including Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Arcturus Therapeutics (ARCT), Akero Therapeutics (AKRO), ESSA Pharma (EPIX), and Annexon (ANNX).

Xeris Pharmaceuticals (NASDAQ:XERS) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Xeris Pharmaceuticals and Phibro Animal Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xeris Pharmaceuticals02102.33
Phibro Animal Health11001.50

Xeris Pharmaceuticals currently has a consensus target price of $13.00, suggesting a potential upside of 207.33%. Phibro Animal Health has a consensus target price of $21.50, suggesting a potential downside of 12.39%. Given Xeris Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Xeris Pharmaceuticals is more favorable than Phibro Animal Health.

Valuation and Earnings

This table compares Xeris Pharmaceuticals and Phibro Animal Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Pharmaceuticals$2.72 million92.94$-125,580,000.00($4.81)-0.88
Phibro Animal Health$800.40 million1.24$33.55 million$1.0822.72

Phibro Animal Health has higher revenue and earnings than Xeris Pharmaceuticals. Xeris Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Xeris Pharmaceuticals has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Insider & Institutional Ownership

69.3% of Xeris Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 6.1% of Xeris Pharmaceuticals shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Xeris Pharmaceuticals and Phibro Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xeris Pharmaceuticals-2,037.97%-435.27%-91.81%
Phibro Animal Health5.37%23.70%5.99%

Summary

Phibro Animal Health beats Xeris Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Xeris Pharmaceuticals (NASDAQ:XERS) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Xeris Pharmaceuticals and Enanta Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xeris Pharmaceuticals02102.33
Enanta Pharmaceuticals13302.29

Xeris Pharmaceuticals currently has a consensus target price of $13.00, suggesting a potential upside of 207.33%. Enanta Pharmaceuticals has a consensus target price of $65.2857, suggesting a potential upside of 33.92%. Given Xeris Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Xeris Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Valuation and Earnings

This table compares Xeris Pharmaceuticals and Enanta Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Pharmaceuticals$2.72 million92.94$-125,580,000.00($4.81)-0.88
Enanta Pharmaceuticals$122.47 million8.03$-36,170,000.00($0.89)-54.78

Enanta Pharmaceuticals has higher revenue and earnings than Xeris Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Xeris Pharmaceuticals and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xeris Pharmaceuticals-2,037.97%-435.27%-91.81%
Enanta Pharmaceuticals-29.53%-3.75%-3.53%

Volatility and Risk

Xeris Pharmaceuticals has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Insider & Institutional Ownership

69.3% of Xeris Pharmaceuticals shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 6.1% of Xeris Pharmaceuticals shares are held by insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Enanta Pharmaceuticals beats Xeris Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Arcturus Therapeutics (NASDAQ:ARCT) and Xeris Pharmaceuticals (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

74.3% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 69.3% of Xeris Pharmaceuticals shares are held by institutional investors. 12.6% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 6.1% of Xeris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Arcturus Therapeutics and Xeris Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcturus Therapeutics25402.18
Xeris Pharmaceuticals02102.33

Arcturus Therapeutics presently has a consensus price target of $70.6667, suggesting a potential upside of 90.99%. Xeris Pharmaceuticals has a consensus price target of $13.00, suggesting a potential upside of 207.33%. Given Xeris Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Xeris Pharmaceuticals is more favorable than Arcturus Therapeutics.

Volatility & Risk

Arcturus Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Xeris Pharmaceuticals has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500.

Valuation & Earnings

This table compares Arcturus Therapeutics and Xeris Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$20.79 million46.77$-25,990,000.00($2.15)-17.21
Xeris Pharmaceuticals$2.72 million92.94$-125,580,000.00($4.81)-0.88

Arcturus Therapeutics has higher revenue and earnings than Xeris Pharmaceuticals. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Xeris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Arcturus Therapeutics and Xeris Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcturus Therapeutics-506.70%-52.32%-33.21%
Xeris Pharmaceuticals-2,037.97%-435.27%-91.81%

Summary

Arcturus Therapeutics beats Xeris Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Akero Therapeutics (NASDAQ:AKRO) and Xeris Pharmaceuticals (NASDAQ:XERS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Valuation and Earnings

This table compares Akero Therapeutics and Xeris Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akero TherapeuticsN/AN/A$-43,760,000.00($2.90)-9.57
Xeris Pharmaceuticals$2.72 million92.94$-125,580,000.00($4.81)-0.88

Akero Therapeutics has higher earnings, but lower revenue than Xeris Pharmaceuticals. Akero Therapeutics is trading at a lower price-to-earnings ratio than Xeris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Akero Therapeutics and Xeris Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akero TherapeuticsN/A-40.84%-38.33%
Xeris Pharmaceuticals-2,037.97%-435.27%-91.81%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Akero Therapeutics and Xeris Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akero Therapeutics00703.00
Xeris Pharmaceuticals02102.33

Akero Therapeutics presently has a consensus price target of $57.2857, suggesting a potential upside of 106.36%. Xeris Pharmaceuticals has a consensus price target of $13.00, suggesting a potential upside of 207.33%. Given Xeris Pharmaceuticals' higher possible upside, analysts clearly believe Xeris Pharmaceuticals is more favorable than Akero Therapeutics.

Insider and Institutional Ownership

83.5% of Akero Therapeutics shares are owned by institutional investors. Comparatively, 69.3% of Xeris Pharmaceuticals shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by company insiders. Comparatively, 6.1% of Xeris Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Akero Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Xeris Pharmaceuticals has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.

Summary

Akero Therapeutics beats Xeris Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

ESSA Pharma (NASDAQ:EPIX) and Xeris Pharmaceuticals (NASDAQ:XERS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.

Profitability

This table compares ESSA Pharma and Xeris Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ESSA PharmaN/A-46.31%-45.08%
Xeris Pharmaceuticals-2,037.97%-435.27%-91.81%

Insider & Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 69.3% of Xeris Pharmaceuticals shares are owned by institutional investors. 6.1% of Xeris Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares ESSA Pharma and Xeris Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ESSA PharmaN/AN/A$-23,440,000.00($1.04)-27.28
Xeris Pharmaceuticals$2.72 million92.94$-125,580,000.00($4.81)-0.88

ESSA Pharma has higher earnings, but lower revenue than Xeris Pharmaceuticals. ESSA Pharma is trading at a lower price-to-earnings ratio than Xeris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ESSA Pharma has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Xeris Pharmaceuticals has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for ESSA Pharma and Xeris Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ESSA Pharma00503.00
Xeris Pharmaceuticals02102.33

ESSA Pharma presently has a consensus target price of $28.80, suggesting a potential upside of 1.52%. Xeris Pharmaceuticals has a consensus target price of $13.00, suggesting a potential upside of 207.33%. Given Xeris Pharmaceuticals' higher possible upside, analysts plainly believe Xeris Pharmaceuticals is more favorable than ESSA Pharma.

Summary

ESSA Pharma beats Xeris Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Xeris Pharmaceuticals (NASDAQ:XERS) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Xeris Pharmaceuticals and Annexon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xeris Pharmaceuticals-2,037.97%-435.27%-91.81%
AnnexonN/A-566.22%-32.99%

Insider and Institutional Ownership

69.3% of Xeris Pharmaceuticals shares are held by institutional investors. Comparatively, 91.2% of Annexon shares are held by institutional investors. 6.1% of Xeris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Xeris Pharmaceuticals and Annexon's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Pharmaceuticals$2.72 million92.94$-125,580,000.00($4.81)-0.88
AnnexonN/AN/A$-37,180,000.00N/AN/A

Annexon has lower revenue, but higher earnings than Xeris Pharmaceuticals.

Analyst Ratings

This is a breakdown of current ratings and target prices for Xeris Pharmaceuticals and Annexon, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xeris Pharmaceuticals02102.33
Annexon00503.00

Xeris Pharmaceuticals currently has a consensus price target of $13.00, suggesting a potential upside of 207.33%. Annexon has a consensus price target of $34.3333, suggesting a potential upside of 37.72%. Given Xeris Pharmaceuticals' higher possible upside, equities research analysts clearly believe Xeris Pharmaceuticals is more favorable than Annexon.

Summary

Annexon beats Xeris Pharmaceuticals on 6 of the 10 factors compared between the two stocks.


Xeris Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.54-0.1%$992.72 million$800.40 million23.15News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.75-1.1%$983.39 million$122.47 million-26.79News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.00-1.8%$972.36 million$20.79 million-12.76
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.76-1.9%$965.22 millionN/A-12.79
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.37-0.2%$958.34 millionN/A-26.27News Coverage
Annexon logo
ANNX
Annexon
1.9$24.93-0.9%$951.28 millionN/A0.00
Humanigen logo
HGEN
Humanigen
1.6$17.25-1.9%$922.56 millionN/A0.00
Radius Health logo
RDUS
Radius Health
1.3$19.49-2.0%$913.96 million$173.32 million-7.99News Coverage
Prothena logo
PRTA
Prothena
2.3$22.78-3.1%$911.34 million$810,000.00-8.90News Coverage
Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25-2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$35.87-0.4%$881.43 millionN/A-10.64Analyst Report
News Coverage
Gap Down
Merus logo
MRUS
Merus
1.6$23.06-1.0%$879.21 million$31.13 million-7.51Analyst Report
Analyst Revision
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$16.75-0.0%$861.92 millionN/A0.00
Affimed logo
AFMD
Affimed
1.6$9.74-19.0%$860.30 million$23.96 million-16.51Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Epizyme logo
EPZM
Epizyme
1.8$8.37-0.6%$851.94 million$23.80 million-3.75
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.89-0.6%$848.58 million$322.36 million127.79
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.33-1.3%$810.86 million$296.70 million47.61
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.57-7.5%$791.51 millionN/A0.00Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$26.95-4.7%$753.06 million$148.36 million-7.00News Coverage
Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.02-1.2%$747.83 million$40.89 million-3.46
Veru logo
VERU
Veru
1.4$10.35-0.3%$744.29 million$42.59 million-36.96
Ardelyx logo
ARDX
Ardelyx
1.6$7.44-5.6%$734.18 million$5.28 million-7.37Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
Chimerix logo
CMRX
Chimerix
1.3$8.45-2.1%$723.99 million$12.52 million-14.82News Coverage
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.82-1.8%$716.29 million$2.22 million-16.59
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$3.05-3.3%$708.43 million$64.61 million-4.49Upcoming Earnings
Analyst Upgrade
Gap Down
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.50-0.0%$686.58 million$19.56 million-19.78High Trading Volume
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.74-3.3%$660.12 millionN/A-2.46Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$28.38-13.7%$655.29 million$13.80 million-13.71Insider Selling
High Trading Volume
News Coverage
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-5.6%$651.22 million$143.01 million-1.19Gap Down
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$19.86-9.5%$640.68 millionN/A-10.56Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$26.15-0.1%$635.65 million$12.69 million-12.57
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$17.62-1.3%$630.96 million$6.83 million-18.16News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.66-5.2%$628.85 million$5.09 million-6.10Analyst Upgrade
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.88-2.4%$628.47 million$9.64 million-5.36
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.82-3.0%$624.78 million$17.26 million-4.12Earnings Announcement
Analyst Revision
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$12.32-9.9%$598.21 millionN/A-6.32Analyst Upgrade
News Coverage
Gap Down
Evolus logo
EOLS
Evolus
1.1$13.58-2.4%$593.89 million$34.92 million-6.69Analyst Report
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.23-2.0%$590.00 millionN/A-16.31Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.87-6.3%$571.13 million$8 million-7.70Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.04-4.1%$568.85 millionN/A-9.33Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.52-3.3%$567.69 millionN/A-4.47News Coverage
Gap Up
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.07-4.9%$563.81 million$1.19 million-7.11Insider Buying
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
0.0$14.44-2.2%$557.76 millionN/A0.00Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26-1.8%$554.59 million$59.29 million-21.73
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.20-5.2%$553.64 millionN/A-5.29Analyst Upgrade
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.56-0.9%$549.30 million$195.89 million118.75News Coverage
SIGA
SIGA Technologies
0.3$7.10-0.6%$544.91 million$26.74 million17.75
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.